Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma

Table 1 Correlation between expression of erythropoietin, erythropoietin receptor and vascular endothelial growth factor

EpoR	Epo			VEGF
	Low expression	High expression	P value	Low expression	High expression	P value
0	24	44	0.018	22	46	0.001
1	20	84		60	44

EpoR: Erythropoietin receptor; Epo: Erythropoietin; VEGF: Vascular endothelial growth factor.

Table 2 Correlation between protein expression and clinicopathological parameters of gastric adenocarcinoma patients (χ² test)

	Case (n = 172)	Epo			EpoR			VEGF
		Low	High	P value	Low	High	P value	Low	High	P value
Age group				0.557			0.001			0.115
< 60	107	29	78		53	54		46	61
≥ 60	65	15	50		15	50		36	29
Gender				0.19			0.822			0.428
Male	108	24	84		42	66		54	54
Female	64	20	44		26	38		28	36
Lauren type				0.018			0.475			0.001
Intestinal	64	22	42		28	36		42	22
Diffusal	70	10	60		28	42		28	42
Mixed	38	12	26		12	26		12	26
WHO type				0.07			0.013			0.734
Tubular	142	40	102		64	78		70	72
Mucinous	12	2	10		2	10		4	8
Papillary	4	2	2		0	4		2	2
Signet-ring cell	14	0	14		2	12		6	8
Lymph node involvement				0.004			0.008			0.011
No	34	10	24		16	18		20	14
1	42	18	24		8	34		26	16
> 1	96	16	80		44	52		36	60
TNM stage				0			0.041			0.007
I	10	4	6		4	6		2	8
II	18	8	10		6	12		14	4
III	80	28	52		24	56		32	48
IV	64	4	60		34	30		34	30
VEGF expression				0.298			0.001
Low	82	18	64		22	60
High	90	26	64		46	44

EpoR: Erythropoietin receptor; Epo: Erythropoietin; VEGF: Vascular endothelial growth factor; WHO: World Health Organization.

Table 3 Multivariate analysis (cox regression model)

Variable	B	SE	Wald	df	Sig	R
LN metastasis	0.514	0.161	10.212	1	0.001	0.096
Epo	0.502	0.257	3.810	1	0.051	0.045
TNM	0.357	0.162	4.856	1	0.028	0.056

Epo: Erythropoietin; LN: Lymph node.